• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

    10/8/24 4:54:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TLPH alert in real time by email

    SAN MATEO, Calif., Oct. 8, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit and will be available for 1x1 meetings with registered investors. The summit is being held on October 15-17, 2024.

    Event:  2024 Maxim Healthcare Virtual Summit

    Date:   October 16, 2024

    Time:   3:00 PM ET / 12:00 Noon PT

    Webcast link:  2024 Maxim Healthcare Virtual Summit

    About Talphera, Inc.

    Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).

    This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

    Talphera Logo (PRNewsfoto/Talphera, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-participate-in-fireside-chat-at-the-2024-maxim-healthcare-virtual-summit-302270671.html

    SOURCE Talphera, Inc.

    Get the next $TLPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLPH

    DatePrice TargetRatingAnalyst
    1/28/2025$4.00Buy
    Rodman & Renshaw
    More analyst ratings

    $TLPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

      Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million Three new clinical study sites activated and screening patients thus far in 2025, with five additional sites expected by mid-year, for a total of 13 Conference call and webcast to be held Wednesday, May 14, 2025 at 4:30 pm ET SAN MATEO, Calif., May 14, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2025 financial res

      5/14/25 4:05:00 PM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

      SAN MATEO, Calif., May 7, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2025 financial results after market close on Wednesday, May 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link post

      5/7/25 4:05:00 PM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 Talphera expects the registrational NEPHRO CRRT study to be completed by the end of 2025 Cash and investments at December 31, 2024 of $8.9 million, together with the private placement financing recently announced of up to $14.8 million, expected to provide capital through target completion of the NEPHRO study in the fourth quarter of 2025 Conference call and webcast to be held Monday, March 31, 2025 at 4:30 pm ET SAN MATEO, Calif., March 31, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and

      3/31/25 4:05:00 PM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care